Quick Answer
Sunshine Biopharma Inc. reported Total Revenue of $34.87 million for the year ending 2024.
- Sunshine Biopharma Inc. showed an increase of +44.7% in Total Revenue from 2023 to 2024.
- This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $0.00 | Q3 2017: $0.00 | Q1 2018: $91.2 thousand | Q2 2018: $0.00 | Q3 2018: $0.00 | Q1 2019: $206.00 | Q2 2019: $3.0 thousand | Q3 2019: $7.3 thousand | Q1 2020: $11.1 thousand | Q2 2020: $15.1 thousand | Q3 2020: $17.2 thousand | Q1 2021: $40.1 thousand | Q2 2021: $52.9 thousand | Q3 2021: $50.4 thousand | Q1 2022: $122.6 thousand | Q2 2022: $150.3 thousand | Q3 2022: $132.8 thousand | Q1 2023: $4.89 million | Q2 2023: $5.56 million | Q3 2023: $5.96 million | Q1 2024: $7.54 million | Q2 2024: $9.30 million | Q3 2024: $8.44 million | Q1 2025: $8.90 million | Q2 2025: $9.41 million | Q3 2025: $9.42 million.
- Historical annual values: Fiscal year 2024: $34.87 million | Fiscal year 2023: $24.09 million | Fiscal year 2022: $4.35 million | Fiscal year 2021: $228.4 thousand | Fiscal year 2020: $71.4 thousand | Fiscal year 2019: $21.1 thousand | Fiscal year 2018: $0.00 | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: